 Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.As such, it "grabs" onto fungal hsp90, hence its proposed trade name.Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.